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and infection prevention
Specific Care Question :
In the child who requires a urinary catheter (Foley) what is the efficacy, cost effectiveness and antimicrobial resistance of
silver coated catheters versus catheters without silver coating?
Question Originator:
Angela Myers, MD
Plain Language Summary from the Office of Evidence Based Practice:
We make a weak recommendation not to use silver coated silicone urinary catheters based on low quality evidence.
Alternative approaches are likely to be better for some patients under some circumstances. Further research (if performed) is likely to
have an important influence on our confidence in the estimate of effect and may change the estimate. Data for this analysis was
obtained from 3 single studies and one meta analysis.
The studies included in the meta analysis were split into two groups: pre 1995 and post 1995. This split occurs because the
reported estimates of effect are markedly different within the two timeframes. The Number Needed to Treat (NNT) from studies
published before 1995 is 4, meaning an infection will be prevented in every fourth patient in whom a silver coated urinary catheter is
used. Juxtapose this to the NNT from studies published after 1995, where the NNT is 98, or an infection will be prevented in every
98th patient in whom a silver coated urinary catheter is used.
More recently, two large cohort studies (Karchmer, Giannetta, Muto, Strain, & Farr, 2000; Rupp et al., 2004) showed
decreased number of infections per patient days and per catheter days. Both cohorts are before and after studies, where hospital wards
were stocked with the silver alloy urinary catheters and rates were compared with historical rates. The major weakness of this design
is that other factors other than the urinary catheter may have influenced the decrease, such as aggressive hand washing campaigns,
changes in the procedures to place the catheters, etc
Finally, the one randomized control trial (RCT) (Pickard et al., 2012).showed that the odds of getting an urinary tract infection
while the urinary catheter is in place, as well as infection one to six weeks after the catheter is removed, are the same. However,
within one week after catheter removal, the odds of getting an infection were significantly lower in the silver coated urinary catheter
group.
Only one of the studies included pediatric subjects (Rupp, et al., 2004). Pediatric units represented 20% of the hospital units
included in the sample. Data from the units were not analyzed separately.
All urinary catheters used in the included studies were latex catheters. A major producer of urinary catheters (C.R.Bard) does
make silver coated silicone catheters that can be used in a pediatric population.
No harm data was published. The Manufacturer and User Facility Device Experience (MAUDE) Database
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm was searched for reported problems of silver coated urinary
catheters. Reported problems included: (a) unable to remove the catheter, (b) the catheter stops draining, and (c) hematuria.
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EBP Scholars responsible for analyzing the literature:
Jamie Menown, RN
Teresa Tobin RRT
Joyce McCollum RN
EBP team member responsible for reviewing, synthesizing, and developing this literature:
Nancy Allen, MS, RD
Search Strategy and Results:
Search completed on February 28, 2013
("Urinary Catheterization"[Mesh] OR "Urinary Catheters"[Mesh] OR "Foley"[TIAB]) AND ("Silver"[Mesh] OR "silver"[TIAB])
AND English[lang]
109 results
("Urinary Tract Infections/prevention and control"[Mesh] OR "Urinary Catheterization"[Mesh] OR "Urinary Catheters"[Mesh]
OR "Foley"[TIAB]) AND ("Silver"[Mesh] OR "silver"[TIAB]) AND English[lang]
114 results
From this list, Dr. Myers selected five articles to be included in the review. Four studies (three randomized control trials and one
meta-analysis were included in this review.
Studies included in this review:
Drekonja, D. M., Kuskowski, M. A., Wilt, T. J., & Johnson, J. R. (2008). Antimicrobial urinary catheters: a systematic review. Expert
Rev Med Devices, 5(4), 495-506. doi: 10.1586/17434440.5.4.495
Karchmer, T. B., Giannetta, E. T., Muto, C. A., Strain, B. A., & Farr, B. M. (2000). A randomized crossover study of silver-coated
urinary catheters in hospitalized patients. Arch Intern Med, 160(21), 3294-3298. doi: ioi00038 [pii]
Pickard, R., Lam, T., MacLennan, G., Starr, K., Kilonzo, M., McPherson, G., . . . N'Dow, J. (2012). Antimicrobial catheters for
reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre
randomised controlled trial. Lancet, 380(9857), 1927-1935. doi: 10.1016/S0140-6736(12)61380-4
Rupp, M. E., Fitzgerald, T., Marion, N., Helget, V., Puumala, S., Anderson, J. R., & Fey, P. D. (2004). Effect of silver-coated urinary
catheters: efficacy, cost-effectiveness, and antimicrobial resistance. Am J Infect Control, 32(8), 445-450. doi:
S0196655304004742
Studies not included in this review with rationale for exclusion:
Johnson, J. R., Kuskowski, M. A., & Wilt, T. J. (2006). Systematic review: antimicrobial urinary catheters to prevent catheter-
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associated urinary tract infection in hospitalized patients. Ann Intern Med, 144(2), 116-126. doi: 144/2/116 [pii] Included the
same studies as (Drekonja, Kuskowski, Wilt, & Johnson, 2008).
Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (RevMan 5.1.7), was used to synthesize three of the included
studies. The meta-analysis was synthesized by GRADE Profiler (GRADEPro).
Updated: April 26, 2013, May 6, 2013, May 16, 2013
Tables:
The included meta-analysis by Drekonja (2008) included nine RCTs. The studies were split into those done pre and post 1995, and
reported separately. For pre 1995 studies (N=483) the OR = 0.24, 95% CI [0.15, 0.4] and the NNT was 4 (See Table 1). For post
studies (N=12288) the OR= 0.79, 95% CI [0.66, 0.94] and the NNT was 98 (See Table 2.).
Table 1. Infection in catheters, pre 1995

Quality assessment

No of patients

Effect
Quality

No of
studies

Design

Risk of
bias

Silver treated
Non silver
Other
urinary catheters
Inconsistency Indirectness Imprecision
coated
considerations made prior to
catheters
1995 be used

Infection catheters pre 1995
4
randomized serious1,2 no serious
trials
inconsistency

no serious
indirectness

no serious
imprecision

none

26/216
(12%)

94/267
(35.2%)

39.2%
1
2

Relative
(95% CI)

Importance

Absolute

OR 0.24 237 fewer per
CRITICAL

(0.15 to 1000 (from 174 MODERATE
0.4)
fewer to 277
fewer)
258 fewer per
1000 (from 187
fewer to 304
fewer)

Attrition not reported
Allocation concealment is not defined
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Table 2. Infection in catheters, post 1995
Quality assessment

No of patients

Effect
Quality Importance

No of
Risk of
Other
Design
Inconsistency
Indirectness Imprecision
studies
bias
considerations
Infection catheters post 1995
5
randomized serious1 no serious
no serious
serious2
none
trials
inconsistency
indirectness

Made post1995 Silver

Control

238/5986
(4%)

316/6302
(5%)

Relative
(95% CI)
OR 0.79
(0.66 to
0.94)

11.9%
1
2

Absolute
10 fewer per 1000  CRITICAL
(from 3 fewer to 16 LOW
fewer)
23 fewer per 1000
(from 6 fewer to 37
fewer)

2 of the 5 studies used alternate week randomization
Wide confidence intervals on 3 of the 5 included studies

Figures:
Pickard, et al. (2012) measured catheter associated urinary tract infection while the catheter was in place (N= 4241). An OR for
acquiring a UTI equaled 1.05, 95% CI [0.65. 1.71] and an NNT > 150. It is important to note that the confidence interval for the OR
crosses 1 and therefore we cannot definitively report that patients benefit with the use of a silver coated urinary catheter when UTI
while the catheter is in place as an outcome (see Figure 1).
Figure 1. UTI while the catheter is in place.
Study or Subgroup
Pickard 2012

Silver
Events Total
34 2097

Total (95% CI)
2097
Total events
34
Heterogeneity: Not applicable
Test for overall effect: Z = 0.21 (P = 0.83)

Control
Events Total Weight
33 2144 100.0%
2144

100.0%

Odds Ratio
M-H, Fixed, 95% CI
1.05 [0.65, 1.71]

Odds Ratio
M-H, Fixed, 95% CI

1.05 [0.65, 1.71]

33
0.01

0.1
1
10
100
Favors silver Favors control
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Pickard, et al. (2012) also measured UTI within one week of catheter removal (N=4241). An OR for acquiring a UTI equaled 3.17,
95% CI [2.13, 4.72], and a Number Needed to Harm (NNH) of 32. This means one in about every 32 patients will have a UTI within
one week of catheter removal compared to the control group (see Figure 2).
Figure 2. UTI within one week of catheter removal.
Study or Subgroup
Pickard 2012
Total (95% CI)

Silver
Events Total
99

Control
Events Total

2097

33

2097

Total events
99
Heterogeneity: Not applicable
Test for overall effect: Z = 5.67 (P < 0.00001)

Weight

Odds Ratio
M-H, Fixed, 95% CI

2144

100.0%

3.17 [2.13, 4.72]

2144

100.0%

3.17 [2.13, 4.72]

Odds Ratio
M-H, Fixed, 95% CI

33
0.01
0.1
1
10
100
Favors silver Favors control

Finally Pickard, et al. (2012) measured the number of UTIs occurring between 1 and 6 weeks after catheter removal (N=4241).The
analysis resulted in an OR equaling 0.90, 95% CI [0.70, 1.15], and a NNT of 152. It is important to note that the confidence interval
for the OR crosses 1. Therefore we cannot report that patients benefit with the use of a silver coated urinary catheter when acquiring a
UTI between 1 and 6 weeks post catheterization is an outcome (see Figure 3).
Figure 3. UTI infection between 1 and 6 weeks post catheterization
Silver
Control
Odds Ratio
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI
Pickard 2012
127 2097
144 2144 100.0%
0.90 [0.70, 1.15]
Total (95% CI)
2097
2144 100.0%
Total events
127
144
Heterogeneity: Not applicable
Test for overall effect: Z = 0.88 (P = 0.38)

Odds Ratio
M-H, Fixed, 95% CI

0.90 [0.70, 1.15]
0.5 0.7 1 1.5 2
Favors silver Favors control
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Characteristics of included studies:
Pickard 2012
Methods
Participants
Interventions

Outcomes

Notes

RCT
7,102 adult patients undergoing urethral catheterization for an anticipated duration of up to 14 days
Control group (N=2,120) received a standard polytetrafluoroethylene (PTFE)-coated latex catheter
Experimental group (N=1,994) received a silver alloy latex catheter
Experimental group (N=2,008) received a nitrofural impregnated catheter
Primary outcome: incidence of symptomatic catheter-associated UTI, defined as the presence of
participant-reported symptoms of UTI and clinician prescription of antibiotic for a UTI at any time up to 6
weeks after randomization.
Secondary outcomes: incidence of microbiologically confirmed symptomatic CAUTI, incidence of
bacteriuria up to 3 days after catheter removal, changes in health-related quality of life during the 6 weeks
of trial participation, and urethral discomfort related to catheterization.
Both the control and the silver alloy catheters are made with latex, which we wouldn't use at CMH.

Risk of bias table
Bias
Random sequence
generation (selection bias)
Allocation concealment
(selection bias)
Blinding of participants
and personnel
(performance bias)
Blinding of outcome
assessment (detection
bias)

Scholars'
judgment
Low risk
Low risk

Support for judgment
Computer generated randomization
Users accessed the randomization through an automated telephone service or a secure web
site.

Low risk
Blinding was not possible due to the distinctive appearance of each catheter, but risk is low.
Low risk

Participants were also outcome assessors in a way, since participants reported symptoms.
Knowing which catheter they received may have affected detection of symptoms, but all
reports of UTI symptoms were corroborated by an outside physician's prescription of an
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Incomplete outcome data
(attrition bias)

Low risk

Selective reporting
(reporting bias)
Other bias

Low risk

antibiotic.
Across the 3 groups, 6,394 (90%) of 7,102 enrolled were included in the main analysis. Out
of those not included, some did not provide retrospective consent or withdrew their consent,
some became ineligible due to not being catheterized. With such a large sample size, this is
acceptable and all attrition is explained.
All outcomes were reported.

Unclear risk

Critically Appraised Topic (CATs)
Author,
date,
Level of
country, and Patient Group
Evidence
industry of
(Oxford)
funding
Karchmer,
Patients on
See assessment
2000
adult
of bias in the
USA
hospital
RevMan
wards of
table
600 bed
hospital,
including
intensive
care units
and stepdown units.
Excluded
were
pediatric
wards,
obstetrics,

Research design

Significant results

Limitations

Wards were randomized.
First six months
Group 1 wards were stocked with
silver-coated catheters
Group 2 wards were stocked with
uncoated catheters
One Month washout-all wards
stocked with uncoated catheters
Second six months
Group 1 wards were stocked with
uncoated catheters
Group 2 wards were stocked with
silver-coated catheters

The relative risk of
infection per 1000
patient days was
0.79, 95% CI
[0.63-0.99]; P=
0.4) for study
wards randomized
to silver coated
catheters compared
to those
randomized to
uncoated catheters.

Important note to this
study: pediatric
wards were not
included and these
silver-coated
catheters were latex
which we do not use
in our pediatric
hospital due to the
risk of allergic
reaction or potential
sensitivity to latex
due to the risk
factors of the
pediatric population.
This study article
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gynecology
and
psychiatry.

did not indicate if
non-latex catheters
with silver coating
are even available.

Before and after comparison

Rupp 2004
USA

Ten patient
care units at a
tertiary
medical center

Before catheter- an uncoated latex
catheter made by the same
manufacturer
After catheter silver
alloy/hydrogel coated catheter
was introduced November 2000
C. R. Bard, Inc Covington, GA

Following the
introduction of silver
alloy/hydrogel
coated urinary
catheters the overall
rate of UTI per 1000
catheter days was
lower in the group
with the silver
coated urinary
catheters
Catheter days
Silver coated
group- 2.62/1000
catheter days
Uncoated group6.13/1000 catheter
days
P= 0.002

Retrospective design.
Other factors may
have changed over
the four year interval
that had an impact on
urinary tract
infections in patients
who were
catheterized.

Patient days
Silver coated
group- 0.97/1000
patient days
Uncoated group1.67/1000 patient
days
P= 0.002
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